Research Paper Volume 13, Issue 19 pp 22690—22709
Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease
- 1 Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau and Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona 08041, Spain
- 2 Department of Internal Medicine, Endocrinology, Metabolism and Lipid Research Division, Washington University School of Medicine, St Louis, MO 63110, USA
- 3 Institute for Health Science Research Germans Trias i Pujol (IGTP) and Center for Biomedical Research on Liver and Digestive Diseases (CIBEREHD), Madrid 28029, Spain
- 4 Vascular and Renal Translational Research Group, Biomedical Research Institute of Lleida, (IRBLleida), Lleida 25198, Spain
- 5 Department of Endocrinology and Nutrition, Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona 08916, Spain
- 6 B2SLab, Department of Systems Engineering, Automation and Industrial Informatics, Polytechnic University of Catalonia, Barcelona 08034, Spain
- 7 DAP-Cat Group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona 08006, Spain
- 8 Department of Medicine, Barcelona Autonomous University (UAB), Bellaterra 08193, Spain
- 9 Primary Health Care Center Raval Sud, Gerència d’Atenció Primaria, Institut Català de la Salut, Barcelona 08001, Spain
- 10 Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki 00290, Finland
- 11 Abdominal Center Nephrology, University of Helsinki and Helsinki University Central Hospital, Helsinki 00280, Finland
- 12 Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki 00100, Finland
- 13 Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria 3004, Australia
- 14 Faculty of Medicine, University of Vic – Central University of Catalonia (UVic/UCC), Vic 08500, Spain
- 15 Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Barcelona 08907, Spain
Received: April 26, 2021 Accepted: September 29, 2021 Published: October 10, 2021https://doi.org/10.18632/aging.203615
How to Cite
Copyright: © 2021 Castelblanco et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This study assessed the association of CD5L and soluble CD36 (sCD36) with the risk of a cardiovascular event (CVE), including CV death and all-cause mortality in CKD. We evaluated the association of CD5L and sCD36 with a predefined composite CV endpoint (unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular accident, congestive heart failure, arrhythmia, peripheral arterial disease [PAD] or amputation by PAD, aortic aneurysm, or death from CV causes) and all-cause mortality using Cox proportional hazards regression, adjusted for CV risk factors. The analysis included 1,516 participants free from pre-existing CV disease followed up for 4 years. The median age was 62 years, 38.8% were female, and 26.8% had diabetes. There were 98 (6.5%) CVEs and 72 (4.8%) deaths, of which 26 (36.1%) were of CV origin. Higher baseline CD5L concentration was associated with increased risk of CVE (HR, 95% CI, 1.17, 1.0–1.36), and all-cause mortality (1.22, 1.01–1.48) after adjusting for age, sex, diabetes, systolic blood pressure, dyslipidemia, waist circumference, smoking, and CKD stage. sCD36 showed no association with adverse CV outcomes or mortality. Our study showed for the first time that higher concentrations of CD5L are associated with future CVE and all-cause mortality in individuals with CKD.
CKD: chronic kidney disease; CV: cardiovascular; CVD: cardiovascular disease; sCD36: soluble cluster of differentiation 36; CD5L: CD5 molecule-like.